Hsbc Holdings PLC Has $1.88 Million Stake in Embecta Corp. $EMBC

Hsbc Holdings PLC raised its holdings in Embecta Corp. (NASDAQ:EMBC) by 1,268.6% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 212,491 shares of the company’s stock after purchasing an additional 196,965 shares during the period. Hsbc Holdings PLC owned approximately 0.36% of Embecta worth $1,882,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. SG Americas Securities LLC raised its position in shares of Embecta by 138.4% in the first quarter. SG Americas Securities LLC now owns 1,038,948 shares of the company’s stock valued at $9,184,000 after buying an additional 603,106 shares in the last quarter. Ameriprise Financial Inc. grew its position in Embecta by 439.1% during the second quarter. Ameriprise Financial Inc. now owns 709,849 shares of the company’s stock worth $6,878,000 after buying an additional 578,174 shares in the last quarter. Jefferies Financial Group Inc. grew its position in Embecta by 24.9% during the fourth quarter. Jefferies Financial Group Inc. now owns 2,354,971 shares of the company’s stock worth $27,977,000 after buying an additional 470,096 shares in the last quarter. UBS Group AG increased its stake in Embecta by 200.8% during the 4th quarter. UBS Group AG now owns 630,994 shares of the company’s stock worth $7,496,000 after acquiring an additional 421,254 shares during the period. Finally, Wellington Management Group LLP increased its stake in Embecta by 168.2% during the 4th quarter. Wellington Management Group LLP now owns 593,366 shares of the company’s stock worth $7,049,000 after acquiring an additional 372,167 shares during the period. Institutional investors and hedge funds own 93.83% of the company’s stock.

Embecta News Summary

Here are the key news stories impacting Embecta this week:

• Neutral Sentiment: Multiple law firms renewed reminders that a securities class action has been filed against Embecta Corp. and that investors who bought shares between November 25, 2025 and May 4, 2026 face an August 17, 2026 lead-plaintiff deadline. Article: EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit
• Neutral Sentiment: Hagens Berman said it is investigating alleged securities law violations following the lawsuit, which claims Embecta misrepresented the commercial stability of its insulin pen needle business. Article: EMBC Alert: Hagens Berman Investigates Alleged Securities Law Violations at Embecta Corp. (NASDAQ: EMBC) Following Pending Class Action Litigation
• Neutral Sentiment: Other firms, including Rosen, Faruqi & Faruqi, The Gross Law Firm, Bragar Eagel & Squire, Kaplan Fox, Pomerantz, Bernstein Liebhard, and Bleichmar Fonti & Auld, issued similar class-action notices, increasing visibility around the stock but not providing new operational information. Article: EMBC Fraud Notification: Embecta Sued for Fraud Over Misrepresentations about its Insulin Pen Issues
• Neutral Sentiment: Embecta’s reported short interest was listed at 0 shares, offering no sign of meaningful bearish positioning based on the latest update. Article: DEADLINE ALERT for EMBC, FSLR, GTM, BTU

Analyst Ratings Changes

EMBC has been the subject of a number of recent analyst reports. Bank of America cut their target price on Embecta from $11.00 to $3.00 and set an “underperform” rating for the company in a research report on Monday, May 18th. Wall Street Zen downgraded Embecta from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Mizuho cut their price objective on shares of Embecta from $12.00 to $5.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Zacks Research upgraded shares of Embecta from a “strong sell” rating to a “hold” rating in a research note on Friday, July 17th. Finally, BTIG Research downgraded shares of Embecta from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 5th. Three equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Reduce” and an average price target of $11.00.

Embecta Stock Performance

Shares of NASDAQ EMBC opened at $3.29 on Monday. The company has a market cap of $195.20 million, a price-to-earnings ratio of 1.73 and a beta of 0.83. Embecta Corp. has a 12 month low of $2.77 and a 12 month high of $15.55. The stock has a 50-day moving average price of $3.24 and a two-hundred day moving average price of $7.25.

Embecta (NASDAQ:EMBC) last posted its earnings results on Tuesday, May 5th. The company reported $0.27 EPS for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.15). The company had revenue of $221.80 million during the quarter, compared to the consensus estimate of $235.67 million. Embecta had a negative return on equity of 23.96% and a net margin of 10.73%.The firm’s revenue was down 14.4% compared to the same quarter last year. During the same period last year, the company posted $0.70 EPS. Embecta has set its FY 2026 guidance at 1.550-1.75 EPS. On average, sell-side analysts predict that Embecta Corp. will post 1.62 earnings per share for the current year.

Embecta Cuts Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, June 15th. Shareholders of record on Thursday, May 28th were given a $0.01 dividend. The ex-dividend date was Thursday, May 28th. This represents a $0.04 dividend on an annualized basis and a yield of 1.2%. Embecta’s dividend payout ratio (DPR) is currently 2.11%.

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.